Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034364 | 0.90 | ALDH1A1 (0.34) | ALDH1A1MAPTKDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL6847864 | 0.82 | ALDH1A1 (0.41) | ALDH1A1MAPTKDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL6847862 | 0.82 | ALDH1A1 (0.41) | ALDH1A1MAPTKDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL6850475 | 0.80 | ALDH1A1 (0.39) | ALDH1A1MAPTKDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL6850473 | 0.80 | ALDH1A1 (0.39) | ALDH1A1MAPTKDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL28303005 | 0.79 | CYP2A6 (0.47) | ALDH1A1MAPTKDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL7214316 | 0.76 | KDM4E (0.43) | ALDH1A1MAPTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL5769923 | 0.71 | CYP2A6 (0.41) | ALDH1A1MAPTKDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL4820875 | 0.69 | SMN1; SMN2 (0.46) | ALDH1A1MAPTKDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL16419707 | 0.68 | IRAK4 (0.38) | ALDH1A1MAPTKDM4ESMN1; SMN2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613747-B2 | Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| US-6472372-B1 | 6-O-Carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | ALDH1A1 3629/4885MAPT 4095/4885KDM4E 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.